-
- 첨부파일 : EMSO TAT 2024 postser_iLeadBMS_IL2106.pdf (1.5M) - 다운로드
본문
Background
Cyclin-dependent kinase 12 (CDK12) and CDK13, members of the CDK family, contribute to cancer progression, including breast and gastric cancer. Both CDK12 and CDK13 are functionally redundant in maintaining the viability and proliferation of malignant cells. CDK12/13 partners with cyclin K to regulate transcriptional elongation by phosphorylating the C-terminal domain (CTD) Ser 2 of RNA polymerase Ⅱ (Pol Ⅱ).
However, targeting the CDK12/13-cyclin K complexes in cancer is still underexplored.
Here, we report the anti-cancer effects of novel CDK12/13 inhibitors as cyclin K molecular glues on triple-negative breast cancer (TNBC) and gastric cancer.
Cyclin-dependent kinase 12 (CDK12) and CDK13, members of the CDK family, contribute to cancer progression, including breast and gastric cancer. Both CDK12 and CDK13 are functionally redundant in maintaining the viability and proliferation of malignant cells. CDK12/13 partners with cyclin K to regulate transcriptional elongation by phosphorylating the C-terminal domain (CTD) Ser 2 of RNA polymerase Ⅱ (Pol Ⅱ).
However, targeting the CDK12/13-cyclin K complexes in cancer is still underexplored.
Here, we report the anti-cancer effects of novel CDK12/13 inhibitors as cyclin K molecular glues on triple-negative breast cancer (TNBC) and gastric cancer.
댓글목록 0